Benefits of, and barriers to, reactivating dormant trials

  • Lorraine Dearden
  • Ruth Gilbert
  • Katie Harron

Published on 14 October 2015

The UK should follow Ontario and reactivate its treasure trove of dormant trials to generate new science through linkage with administrative data. Many groups stand to benefit. For example, drug regulators could encourage linkage of dormant and new trials to administrative data to monitor long term safety of drugs.

Access

http://www.bmj.com/content/351/bmj.h5298 

The UK should follow Ontario and reactivate its treasure trove of dormant trials to generate new science through linkage with administrative data.  Many groups stand to benefit. For example, drug regulators could encourage linkage of dormant and new trials to administrative data to monitor long term safety of drugs. 

Authors

Person graphic

Lorraine Dearden

Person graphic

Katie Harron

Person graphic

Ruth Gilbert

Journal article details

DOI
10.1136/bmj.h5298
Publisher
BMJ Publishing Group
Issue
October 2015

Suggested citation

L, Dearden and R, Gilbert and K, Harron. (2015). 'Benefits of, and barriers to, reactivating dormant trials' (2015)

Grant

Centre for the Microeconomic Analysis of Public Policy (CPP), 2015-2020

More from IFS

Understand this issue

Policy analysis

NHS workers in scrubs

Progression of nurses within the NHS

report
This report examines the career progression of NHS nurses, how this compares with that of other NHS staff groups and how this has changed over time.

12 April 2024

Academic research